US 9636400
VEGF specific fusion protein antagonist formulations
granted A61KA61K31/4172A61K31/7012
Quick answer
US patent 9636400 (VEGF specific fusion protein antagonist formulations) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K31/4172, A61K31/7012, A61K38/16, A61K38/179